Current Report Filing (8-k)
January 31 2022 - 07:31AM
Edgar (US Regulatory)
0001704287
false
0001704287
2022-01-31
2022-01-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
January 31, 2022
Bluejay Diagnostics, Inc.
(Exact Name of Registrant as Specified in its Charter)
delaware
|
|
001-41031
|
|
47-3552922
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission File No.)
|
|
(I.R.S. Employer
Identification No.)
|
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
(Address of principal executive offices and zip
code)
(844) 327-7078
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed from
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-14(c)).
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol (s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
|
BJDX
|
|
The NASDAQ Stock Market LLC
|
Item 7.01 Regulation FD Disclosure
On
January 31, 2022, Bluejay Diagnostics, Inc. (the “Company”), issued a press release to announce that it has filed a Pre-Submission
package for the Symphony IL-6 Test with the U.S. Food and Drug Administration. A copy of the press release is attached to this report
as Exhibit 99.1 and is incorporated by reference herein.
The
information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed”
for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference
in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified
therein as being incorporated by reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Bluejay Diagnostics Inc.
|
|
|
|
By:
|
/s/ Gordon
Kinder
|
|
|
Gordon Kinder
|
|
|
Chief Financial Officer
|
Dated: January 31, 2022
2
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From Mar 2023 to Mar 2024